(4-amino-2-phenylaminothiazol-5-yl)-(3-fluorophenyl)methanone

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (4-amino-2-phenylaminothiazol-5-yl)-(3-fluorophenyl)methanone
• 英文别名: (4-Amino-2-anilino-1,3-thiazol-5-yl)-(3-fluorophenyl)methanone；(4-amino-2-anilino-1,3-thiazol-5-yl)-(3-fluorophenyl)methanone
• 化学式: C₁₆H₁₂FN₃OS
• 分子量: 313.355
• InChiKey: FKVUXPCXYYHCAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  96.2
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  氰胺 、 3-氟溴代苯乙酮 、 硫代异氰酸苯酯 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 0.25h， 生成 (4-amino-2-phenylaminothiazol-5-yl)-(3-fluorophenyl)methanone
  参考文献：
  名称：

  Development of Highly Potent and Selective Diaminothiazole Inhibitors of Cyclin-Dependent Kinases

  摘要：

  Cyclin-dependent kinases (CDKs) are serine/threonine protein kinases that act as key regulatory elements in cell cycle progression. We describe the development of highly potent diaminothiazole inhibitors of CDK2 (IC50 = 0.0009-0.0015 mu M) from a single hit compound with weak inhibitory activity (IC50 = 15 mu M), discovered by high-throughput screening. Structure-based design was performed using 35 cocrystal structures of CDK2 liganded with distinct analogues of the parent compound. The profiling of compound 51 against a panel of 339 kinases revealed high selectivity for CDKs, with preference for CDK2 and CDK5 over CDK9, CDK1, CDK4, and CDK6. Compound 51 inhibited the proliferation of 13 out of 15 cancer cell lines with IC50 values between 0.27 and 6.9 mu M, which correlated with the complete suppression of retinoblastoma phosphorylation and the onset of apoptosis. Combined, the results demonstrate the potential of this new inhibitors series for further development into CDK-specific chemical probes or therapeutics.

  DOI：

  10.1021/jm301234k

文献信息

• Use of 2,4-diaminothiazole derivatives
  申请人：——

  公开号：US20010039275A1

  公开（公告）日：2001-11-08

  2,4-Diaminothiazole derivatives which inhibit GSK-3 (glycogen synthase kinase-3) and which are useful for the treatment and/or prevention disorders and diseases wherein an inhibition of GSK-3 is beneficial, especially especially Alzheimer's disease, bipolar disorder, IGT (impaired glucose tolerance), Type 1 diabetes, Type 2 diabetes and obesity.

  抑制GSK-3（糖原合成激酶-3）的2,4-二氨基噻唑衍生物，对治疗和/或预防GSK-3抑制有益的疾病和疾病特别有效，尤其是阿尔茨海默病、双相情感障碍、糖耐量受损（IGT）、1型糖尿病、2型糖尿病和肥胖症。
• [EN] 2,4-DIAMINOTHIAZOLE DERIVATIVES AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 (GSK-3) INHIBITORS<br/>[FR] DERIVES DE 2,4-DIAMINOTHIAZOLE
  申请人：NOVO NORDISK AS

  公开号：WO2001056567A1

  公开（公告）日：2001-08-09

  2,4-Diaminothiazole derivatives which inhibit GSK-3 (glycogen synthase kinase-3) and which are useful for the treatment and/or prevention disorders and diseases wherein an inhibition of GSK-3 is beneficial, especially especially Alzheimer's disease, bipolar disorder, IGT (impaired glucose tolerance), Type 1 diabetes, Type 2 diabetes and obesity.

  2,4-二氨基噻唑衍生物抑制GSK-3（糖原合成酶激酶-3），对于治疗和/或预防抑制GSK-3有益的疾病和疾病特别是阿尔茨海默病、双相情感障碍、IGT（糖耐量受损）、1型糖尿病、2型糖尿病和肥胖症具有用处。